Femasys Inc (FEMY) Stock Price, Quote & News

Company Profile

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual b...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 770 500 3910

Fax: 404 581 5903

Website: femasys.com

Address:

3950 Johns Creek Court, Suite 100, Suwanee, United States

SuperGreenToday Jun. 6 at 12:26 AM

$FEMY

0 · Reply

supplySHOCK Jun. 5 at 10:35 PM

$FEMY $CDLX $SMSI $CETX reverse splits

0 · Reply

TwongStocks Jun. 5 at 8:43 PM

Five NASDAQ stocks with reverse splits scheduled on Monday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Monday morning. $CDLX 1 for 10. Will reduce outstanding shares from approx 58.08m to approx 5.81m. $FEMY 1 for 20. Will reduce outstanding shares from approx 60.39m to approx 3.02m. $HUBC 1 for 20. Will reduce outstanding shares from approx 66.60m to approx 3.33m. $KIDZ 1 for 10. Will reduce outstanding Class B shares from approx 11.13m to approx 1.11m. $ZCMD 1 for 31. Will reduce outstanding Class A shares from approx 79.69m to approx 2.57m.

0 · Reply

Itzana Jun. 5 at 8:13 PM

$FEMY it's a fact that people who mislead others have a place waiting for them and its definitely not heaven.

0 · Reply

onethestiff Jun. 5 at 8:09 PM

$FEMY funny how trip trap has disappeared. Kept saying he was a pumper!

3 · Reply

Alican1994 Jun. 5 at 7:54 PM

$FEMY DONT SELL

0 · Reply

MOTeach Jun. 5 at 7:25 PM

$FEMY I agree. I’m pissed at salaries and incompetence and the price to go so low. Fucking morons.

0 · Reply

steve04240 Jun. 5 at 7:22 PM

$FEMY the whole maket is in the pisser today to complicate matters🤢

0 · Reply

steve04240 Jun. 5 at 7:20 PM

$FEMY no way am I selling at all time lows.... I will wait it out for the eventual recovery, or buyout hopefully! Rule number one buy low/ sell high, not the opposite. Fuck I'm pissed

1 · Reply

cjw1979 Jun. 5 at 7:08 PM

$FEMY not worried. These are half broad market moves, half panicking. The SP is down over 2%. Indexes are doing broad, blind sells of their holdings - all low-volume microcaps are getting whacked by that. Good time to buy.

1 · Reply

Femasys Inc trading halted, news pending

2026-05-13T14:46:53.000Z - 23 days ago

Femasys announces CE Mark approval for FemHSG Catheter

May 13, 2026, 9:00 AM EDT - 23 days ago

Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter

May 13, 2026, 7:00 AM EDT - 23 days ago

Femasys Slides: Corporate presentation

May 8, 2026, 4:05 PM EDT - 4 weeks ago

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

May 8, 2026, 8:00 AM EDT - 4 weeks ago

Femasys Quarterly report: Q1 2026

May 8, 2026, 8:00 AM EDT - 4 weeks ago

Femasys Earnings release: Q1 2026

May 5, 2026, 9:00 AM EDT - 4 weeks ago

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Femasys Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Femasys Proxy statement: Proxy filing

2026-04-16T13:56:18.000Z - 7 weeks ago

Femasys drives growth with Israeli market entry for fertility portfolio

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Femasys Proxy statement: Proxy filing

Mar 31, 2026, 4:05 PM EDT - 2 months ago

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Femasys Annual report: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Femasys Earnings release: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Femasys Proxy statement: Proxy filing

2026-03-24T15:20:53.000Z - 2 months ago

Femasys management to meet virtually with Lake Street

2026-03-18T13:05:27.000Z - 2 months ago

Femasys appoints Kenneth Eichenbaum to its Board of Directors

2026-03-10T13:17:37.000Z - 3 months ago

Femasys advances FemBloc to U.S. approval with initiation of trial enrollment

2026-03-03T13:13:48.000Z - 3 months ago

Femasys initiated with a Buy at Lake Street

Feb 27, 2026, 5:26 PM EST - 3 months ago

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-02-26T14:06:51.000Z - 3 months ago

Femasys FemBloc achieved certification under MDSAP

2026-02-23T14:06:46.000Z - 3 months ago

Femasys receives AMA CPT Editorial Panel approval for new CPT code

Feb 23, 2026, 9:00 AM EST - 3 months ago

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

2026-02-03T14:20:28.000Z - 4 months ago

Femasys enters distribution partnership with OR Consulting

2026-01-14T14:15:55.000Z - 5 months ago

Femasys granted 180-day extension by Nasdaq to regain compliance

2026-01-13T14:05:24.000Z - 5 months ago

Femasys announces partnership with Refuah Health Center

Jan 13, 2026, 9:00 AM EST - 5 months ago

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

2025-12-31T21:40:10.000Z - 5 months ago

Femasys files to sell 68.42M shares of common stock for holders

Dec 31, 2025, 7:00 AM EST - 5 months ago

Femasys Registration statement: Registration filing

2025-12-18T14:21:29.000Z - 6 months ago

Femasys secures U.S. FDA clearance for FemVue Controlled device

Dec 18, 2025, 9:15 AM EST - 6 months ago

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Dec 4, 2025, 7:00 AM EST - 6 months ago

Femasys Registration statement: Registration filing

2025-11-25T14:25:20.000Z - 6 months ago

PharmaCyte sells Femasys stake, sees cash position rising to $20M

PMCB

Nov 25, 2025, 9:15 AM EST - 6 months ago

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PMCB

2025-11-20T10:00:27.000Z - 7 months ago

Femasys initiated with a Buy at Laidlaw

Nov 14, 2025, 7:00 AM EST - 7 months ago

Femasys Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 7 months ago

Femasys Earnings release: Q3 2025

2025-11-10T14:16:39.000Z - 7 months ago

Femasys advances global growth with second partner order for FemBloc in Europe

2025-11-03T13:40:39.000Z - 7 months ago

Femasys secures FDA approval to advance final FemBloc trial phase

Nov 3, 2025, 8:30 AM EST - 7 months ago

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

2025-10-22T13:13:02.000Z - 8 months ago

Femasys announces initiation of post-market surveillance study for FemBloc

2025-10-16T18:10:11.000Z - 8 months ago

Femasys jumps with Trump expected to expand IVF access

Oct 16, 2025, 9:00 AM EDT - 8 months ago

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Sep 11, 2025, 9:00 AM EDT - 9 months ago

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Sep 8, 2025, 9:00 AM EDT - 9 months ago

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Aug 25, 2025, 11:44 PM EDT - 10 months ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug 21, 2025, 8:00 AM EDT - 10 months ago

Femasys Registration statement: Registration filing

Aug 20, 2025, 8:00 AM EDT - 10 months ago

Femasys Registration statement: Registration filing

Aug 8, 2025, 4:05 PM EDT - 10 months ago

Femasys Announces Second Quarter Financial Results for 2025

Aug 8, 2025, 8:00 AM EDT - 10 months ago

Femasys Quarterly report: Q2 2025

Aug 8, 2025, 8:00 AM EDT - 10 months ago

Femasys Earnings release: Q2 2025

Aug 6, 2025, 9:00 AM EDT - 10 months ago

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Jul 3, 2025, 8:00 AM EDT - 1 year ago

Femasys Registration statement: Registration filing

Jul 1, 2025, 9:00 AM EDT - 1 year ago

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Jun 25, 2025, 9:00 AM EDT - 1 year ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Jun 17, 2025, 9:00 AM EDT - 1 year ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

May 29, 2025, 4:23 PM EDT - 1 year ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 8, 2025, 5:01 PM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 1 year ago

Femasys Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Femasys Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Femasys Proxy statement: Proxy filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Femasys Proxy statement: Proxy filing

Mar 27, 2025, 9:00 AM EDT - 1 year ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Femasys Annual report: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Femasys Earnings release: Q4 2024

Mar 19, 2025, 9:20 AM EDT - 1 year ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 18, 2025, 9:00 AM EDT - 1 year ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Feb 25, 2025, 9:20 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 11, 2025, 9:00 AM EST - 1 year ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Jan 30, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 16, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 12, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 12, 2024, 7:00 AM EST - 1 year ago

Femasys Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Femasys Earnings release: Q3 2024

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Femasys Quarterly report: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Femasys Earnings release: Q2 2024

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Jun 7, 2024, 8:00 AM EDT - 2 years ago

Femasys Proxy statement: Proxy filing

May 17, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 16, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 9, 2024, 8:30 AM EDT - 2 years ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 9, 2024, 8:00 AM EDT - 2 years ago

Femasys Quarterly report: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Femasys Earnings release: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Apr 18, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

SuperGreenToday Jun. 6 at 12:26 AM

$FEMY

0 · Reply

supplySHOCK Jun. 5 at 10:35 PM

$FEMY $CDLX $SMSI $CETX reverse splits

0 · Reply

TwongStocks Jun. 5 at 8:43 PM

0 · Reply

Itzana Jun. 5 at 8:13 PM

$FEMY it's a fact that people who mislead others have a place waiting for them and its definitely not heaven.

0 · Reply

onethestiff Jun. 5 at 8:09 PM

$FEMY funny how trip trap has disappeared. Kept saying he was a pumper!

3 · Reply

Alican1994 Jun. 5 at 7:54 PM

$FEMY DONT SELL

0 · Reply

MOTeach Jun. 5 at 7:25 PM

$FEMY I agree. I’m pissed at salaries and incompetence and the price to go so low. Fucking morons.

0 · Reply

steve04240 Jun. 5 at 7:22 PM

$FEMY the whole maket is in the pisser today to complicate matters🤢

0 · Reply

steve04240 Jun. 5 at 7:20 PM

$FEMY no way am I selling at all time lows.... I will wait it out for the eventual recovery, or buyout hopefully! Rule number one buy low/ sell high, not the opposite. Fuck I'm pissed

1 · Reply

cjw1979 Jun. 5 at 7:08 PM

1 · Reply

MOTeach Jun. 5 at 6:50 PM

$FEMY think about all our losses going to her ridiculous salary and bonuses. Makes me 🤢.

0 · Reply

Zaksab Jun. 5 at 6:41 PM

$FEMY night night

0 · Reply

Tomlin10 Jun. 5 at 6:39 PM

$FEMY kathy ran this company into the ground. Luckily i traded this a few times over the years which softens this loss some, but still walking away 20k in the hole thanks to the incompetency of this company. 🖕 Kathy and Femasys.

0 · Reply

ppeden Jun. 5 at 5:15 PM

$FEMY I've been here for two years and I pulled out today. I've gone through R/S before and always lost. I hope that is not the case here. I still believe a buy out is where this is heading and I hope the guys that are sticking out win big.

2 · Reply

Severian1 Jun. 5 at 4:49 PM

$FEMY next task is finding bottom post r/s. the question is how long will it take???

1 · Reply

MOTeach Jun. 5 at 4:47 PM

$FEMY criminals

0 · Reply

Drlee5647 Jun. 5 at 4:10 PM

$FEMY

0 · Reply

Zeah Jun. 5 at 3:52 PM

$FEMY Figured they’d have set a long trap going into the R/S, but noooo, extra fade this morning, new ATL, and more to be set. Its like i always say, buy low, DCA lower, let them run it even lower, nice company Kathy

0 · Reply

GuruChartist Jun. 5 at 3:28 PM

$FEMY Post reverse split is the time to buy...after a few days

0 · Reply

goldenxb Jun. 5 at 3:07 PM

$FEMY going to $0 😞

2 · Reply

OccidentalPete Jun. 5 at 2:15 PM

$FEMY Looking forward to $100 price targets once this company finally sells some product

2 · Reply

goldenxb Jun. 5 at 2:15 PM

$FEMY Lots of stocks dropping because folks taking liquidity out in prep for spacex …but none of us have much liquidity left in this one 😭

0 · Reply

Market Cap	21.57M
Revenue (ttm)	2.29M
Net Income (ttm)	-18.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-813.54%
Debt to Equity Ratio	0.47

Volume	2,594,300
Avg Vol	1,153,172
Day's Range	N/A - N/A
Shares Out	60.39M
Stochastic %K	14%
Beta	-2.23
Analysts	Strong Sell
Price Target	$3.00